Global Talks Lung Cancer Forum
Watch this webinar to get updates on advancements in lung cancer treatment, including resectable NSCLC, thoracic surgery, neoadjuvant immunotherapy.
READ MOREYou are about to leave the Clinical Value website now.
Watch this webinar to get updates on advancements in lung cancer treatment, including resectable NSCLC, thoracic surgery, neoadjuvant immunotherapy.
READ MOREWatch the APASL 2024 seminar recording to hear experts share key updates on curative approaches to HCC management, treatment apporaches for BCLC-B uHCC, and real world…
READ MOREMissed the satellite symposium session from ESMO 2023? Access the webcast recording here.
READ MOREMissed the satellite symposium session from ESMO Asia 2023? Access the webcast recording here.
READ MOREThe field of clinical oncology continues to see drastic advancements with non-invasive techniques, such as liquid biopsy being adopted for diagnosing and monitoring cancers in place…
READ MORELung cancer has seen tremendous advancements over the past decade with the emergence of targeted therapies directed against mutant onco-proteins and immune checkpoint inhibitors. Join the…
READ MOREMissed the satellite symposium session from ESMO 2022? Access the webcast recording here.
READ MORETo enable value-based healthcare, several important steps are needed. In this presentation and Q&A, Ingel Demedts discusses the project “Value-based care in lung cancer: a case…
READ MOREThe growing amount of clinical data available for each patient, clinicians need to manage massive genomic information, histological analysis tools, and clinical trials and publications. They…
READ MORETreatment landscape of NSCLC has been evolving dramatically in the past ten years, and biomarker testing is becoming increasingly complex. Join the webinar to hear from…
READ MORESeveral EGFR tyrosine kinase inhibitors are recommended by international guidelines as first-line treatment for patients with EGFR mutations. While tissue biopsy samples continue to be the…
READ MORESeveral EGFR Tyrosine Kinase Inhibitors are recommended by international guidelines as first-line treatment for patients with EGFR mutations. A robust and approved Companion Diagnostic (CDx) assay…
READ MOREVarious diagnostic tools play indispensable roles in diagnosing, staging, treatment selection & monitoring of lung cancer patients. Join the webinar to hear from pulmonologist Dr James…
READ MOREWatch the APASL 2023 symposium recording to hear experts share key updates on HCC surveillance, diagnosis, uHCC management and adj HCC systemic treatment.
READ MOREThis presentation has 2 parts. In the first part of this presentation, Prof. Nobuharu Tamaki discusses the diagnostic utility of PIVKA-II in HCC, and the potential…
READ MOREDetection of HCC at early stages remains a challenge, with less than 20% of patients being diagnosed at an early stage, when they can benefit from…
READ MOREIn this presentation, Prof. Ming Lung Yu discusses the results of his study, which aims to address the diagnostic accuracy of HCC using Elecsys GAAD algorithmic…
READ MOREIn this presentation, Prof. Do Young Kim reviews the results of the APAC expert consensus study on the utilization of PIVKA-II in the surveillance and monitoring…
READ MOREThe liver cancer landscape has been undergoing a period of rapid transformation. From early detection of HCC using new biomarkers, to new immunotherapy treatment options. Watch…
READ MOREJoin our experts for a series of on-demand webinars, focused on clinical insights and knowledge from the fields of oncology, hepatology, interventional radiology, and surgery, to…
READ MOREJoin the webinar to hear speakers Prof. Henry Chan and Prof. Hui Chuan Sun as they discuss the use of PIVKA-II and GAAD score as promising…
READ MOREJoin the webinar to hear speakers Prof. Henry Chan, and Assoc. Prof. Teerha Piratvisuth as they discuss the clinical usefulness of PIVKA-II in HCC surveillance, as…
READ MORE